Tomas Kiselak, Director, 10% Owner at Dianthus Therapeutics, Inc. /DE/ (DNTH), bought 30,000 shares at $13.15 ($395K) on 2023-09-26, disclosed to the SEC on 2023-09-28.
Open-market purchase of $394k DNTH by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Something here stands out, but not much.
| Filing → |